Mainz Biomed Prices $8M Follow-On Offering
Ticker: MYNZ · Form: 6-K · Filed: Dec 13, 2024 · CIK: 1874252
| Field | Detail |
|---|---|
| Company | Mainz Biomed N.V. (MYNZ) |
| Form Type | 6-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $8.0 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: offering, financing, press-release
TL;DR
Mainz Biomed just priced an $8M follow-on offering at market rate.
AI Summary
Mainz Biomed N.V. announced on December 12, 2024, the pricing of a follow-on offering of $8.0 million. The offering was priced at-the-market under Nasdaq rules. This information is being furnished as part of a Form 6-K filing.
Why It Matters
This capital raise provides Mainz Biomed with additional funds, potentially for operations, research, or expansion, which could impact its future development and stock performance.
Risk Assessment
Risk Level: medium — Follow-on offerings can dilute existing shareholders and indicate a need for capital, but pricing at-the-market suggests confidence in current valuation.
Key Numbers
- $8.0M — Follow-on Offering (Capital raised by Mainz Biomed)
Key Players & Entities
- Mainz Biomed N.V. (company) — Registrant
- $8.0 million (dollar_amount) — Follow-on offering amount
- December 12, 2024 (date) — Press release date
- Nasdaq (company) — Exchange where offering was priced
FAQ
What is the purpose of the $8.0 million follow-on offering?
The filing does not specify the exact use of proceeds, but such offerings typically fund operations, research and development, or general corporate purposes.
When was the press release announcing the offering dated?
The press release announcing the pricing of the follow-on offering was dated December 12, 2024.
Under what rules was the offering priced?
The offering was priced at-the-market under Nasdaq rules.
What is the SEC file number for Mainz Biomed N.V.?
The SEC file number for Mainz Biomed N.V. is 001-41010.
Is this filing incorporated into any other registration statements?
Yes, the information in this Form 6-K is incorporated by reference into Mainz Biomed's Registration Statement on Form F-3 (File No. 333-269091).
Filing Stats: 220 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-12-13 08:00:20
Key Financial Figures
- $8.0 Million — ldquo;Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market
Filing Documents
- ea0224721-6k_mainz.htm (6-K) — 9KB
- ea022472101ex99-1_mainz.htm (EX-99.1) — 8KB
- 0001213900-24-108611.txt ( ) — 18KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant’s name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Other Events Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release dated December 12, 2024 entitled “Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules”. The information contained in this Report on Form 6-K is hereby incorporated by reference into our Registration Statement on Form F-3 (File No. 333-269091 ). Exhibit No. Exhibit 99.1 Press Release entitled “Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules” 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 13, 2024 By: /s/ William J. Caragol Name: William J. Caragol Title: Chief Financial Officer 2